Evidence-informed pharmacology monograph updated 10 November 2026. Educational material; individualized treatment requires clinical assessment and current local prescribing information.
Overview and classification
Indomethacin (indometacin) is a potent nonselective NSAID in the indoleacetic acid derivative family, not the propionic-acid family. It inhibits COX-mediated prostaglandin synthesis and has recognized anti-inflammatory and analgesic effects. Its relatively high CNS, GI and renal adverse-effect burden often makes better-tolerated alternatives preferable for chronic use [1,2].
Mechanism and pharmacokinetics
By inhibiting COX-1 and COX-2, indomethacin reduces prostaglandin production, edema, inflammation and pain. Unlike disease-modifying antirheumatic drugs, it does not prevent progression of rheumatoid arthritis. Oral products have differing release characteristics; indomethacin undergoes hepatic metabolism and enterohepatic cycling with renal and biliary excretion. Dosage and kinetics depend on formulation and organ function [1].
Therapeutic roles
Indomethacin is labeled for moderate-to-severe rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute painful shoulder (bursitis/tendinitis) and acute gouty arthritis. It may also have specialist off-label applications in selected primary headache syndromes. Distinct IV indomethacin products have been used by neonatologists to pharmacologically close patent ductus arteriosus; such neonatal specialist use is not equivalent to prescribing oral indomethacin for adults [1,2].
GI, CNS and cardiovascular toxicity
GI ulceration, bleeding or perforation can be severe; headache, dizziness, confusion and other CNS effects are relatively prominent and may limit use in older adults. Hypertension, edema, heart failure exacerbation and AKI can occur, as can serious cardiovascular thrombotic events. Monitor blood pressure, symptoms of occult GI bleeding, renal function and relevant CBC/liver tests during prolonged treatment [1,2].
Pregnancy and renal cautions
The 2024 INDOCIN label advises limiting NSAID use from about 20 to 30 weeks gestation because of fetal renal dysfunction and oligohydramnios, and avoiding use at around 30 weeks onward because of premature ductus arteriosus closure. This is distinct from specialist neonatal ductal closure after birth. Avoid or reassess indomethacin with advanced CKD, dehydration and ongoing gastrointestinal bleeding [2].
Interactions and practice points
Concurrent anticoagulants, antiplatelets, aspirin/NSAIDs, glucocorticoids and serotonergic antidepressants may increase GI bleeding. NSAIDs may reduce the effectiveness of some antihypertensives and increase AKI risk with ACEi/ARB/diuretics. Indomethacin can increase lithium concentration and may alter methotrexate clearance. Use the lowest effective dose and limit duration when possible [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- US Food and Drug Administration. INDOCIN (indomethacin) capsules: prescribing information, 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/016059s102lbl.pdf
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.